CannLabs, Inc. (CANL) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Denver, CO, 미국. 현재 CEO는 Mark C. Mirken.
CANL 을(를) 보유 IPO 날짜 2014-06-13, 37 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $93.32K.
CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. is based in Denver, Colorado.
